By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
2d
Pharmaceutical Technology on MSNPfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
7don MSN
Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.
The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...
President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.
Robert F. Kennedy Jr. is set to significantly cut the size of HHS, reshaping the nation’s health agencies and closing ...
Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating ...
Italy's Industry Minister Adolfo Urso on Thursday told parliament that Rome would ask the European Union to immediately ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating ...
The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results